Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5192_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Dedications
- •Contributors
- •Acknowledgments
- •Preface
- •1 Basic science
- •1.1 Structure and function of the skin
- •Epidermis
- •Cellular biology of the epidermis
- •Dermal cells of importance
- •Structural components and cell biology of the dermis
- •1.2 Embryology
- •1.3 Wound healing
- •Dermis
- •1.4 Genetics
- •Basic cell biology of genome
- •Inheritance patterns
- •1.5 Ultraviolet light
- •Ultraviolet light (Fig. 1.8)
- •Minimal erythema dose
- •1.6 Immunology
- •Innate immunity
- •Adaptive immunity
- •1.6.2 Immunologic mediators
- •Cytokines
- •Pattern recognition receptors
- •Antimicrobial proteins (AMPs)
- •The complement system
- •B cells
- •T cells (majority of lymphocytes)
- •Innate lymphoid cells
- •NK cells
- •Mononuclear phagocytes
- •Langerhans cells
- •Dendritic cells
- •Mast cells
- •Eosinophils
- •Neutrophils
- •1.6.4 Major histocompatibility complex
- •1.7 Laboratory techniques
- •1.7.1 Tissue acquisition and processing
- •Polymerase chain reaction (PCR)
- •Quantitative reverse transcriptase PCR (qRT-PCR)
- •16S ribosomal RNA (rRNA) sequencing
- •DNA sequencing
- •RNA sequencing
- •Fluorescence in situ hybridization (FISH)
- •Immunohistochemistry (IHC)
- •Enzyme-linked immunosorbent assay (ELISA)
- •1.7.3 Cellular engineering and gene therapy
- •2 Dermatopharmacology
- •2.1 ANTIHISTAMINES
- •Mechanism
- •Other antihistamines
- •Introduction
- •Mucocutaneous
- •Systemic
- •Teratogenicity
- •Contraindications
- •Interactions
- •2.3 CORTICOSTEROIDS
- •Hypothalamic-pituitary-adrenal (HPA) axis suppression (Box 2.1)
- •Psychiatric changes
- •Contraindications
- •Pregnancy
- •Clinical use
- •Intramuscular CS
- •Pulse IV CS
- •Adalimumab
- •Certolizumab pegol
- •Golimumab
- •Indications
- •Ustekinumab
- •IL-17 inhibitors
- •IL-23 inhibitors
- •Spesolimab
- •Rituximab
- •IL-1 inhibitors
- •Omalizumab
- •Dupilumab
- •Lebrikizumab and tralokinumab
- •Nemolizumab
- •Vismodegib and sonidegib
- •Intralesional CS
- •Monitoring
- •2.4 IMMUNOMODULATORY AGENTS
- •Apremilast and other PDE-4 inhibitors
- •Janus Kinase (JAK) and Tyro inhibitors
- •Agents used in dermatology
- •Laboratory monitoring
- •Azathioprine
- •Important monitoring points
- •Cyclosporine
- •Important pharmacology points
- •Indications
- •Important monitoring points
- •Methotrexate
- •Important pharmacology points
- •Indications and contraindications
- •Important monitoring points
- •Important pharmacology points
- •Indications
- •Monitoring guidelines
- •Cytotoxic agents
- •Hydroxyurea
- •Cyclophosphamide
- •Chlorambucil
- •Antimalarial agents
- •Important pharmacology points
- •Indications
- •Dapsone
- •Important pharmacology points
- •Indications
- •Important monitoring points
- •Etanercept
- •MEK inhibitors (trametinib, cobimetinib, binimetinib)
- •Ipilimumab
- •PD-1 inhibitors (pembrolizumab, nivolumab, cemiplimab) and PD-L1 inhibitors (avelumab, atezolizumab)
- •Imatinib mesylate
- •Ibrutinib
- •Talimogene
- •Mechlorethamine hydrochloride
- •Brentuximab vedotin
- •Mogamulizumab
- •Romidepsin and vorinostat
- •2.6 ANTIMICROBIAL AGENTS
- •Topical antibacterial agents
- •Bacitracin
- •Benzoyl peroxide
- •Metronidazole
- •Azelaic acid
- •Systemic antibacterial agents
- •Penicillins
- •Polymyxin B
- •Neomycin
- •Mupirocin
- •Retapamulin
- •Gentamicin
- •Iodoquinol
- •Cephalosporins
- •Vancomycin
- •Macrolides
- •Fluoroquinolones
- •Tetracyclines
- •Clindamycin
- •Carbapenems
- •Linezolid
- •Daptomycin
- •Others
- •Antiviral agents
- •Acyclovir
- •Valacyclovir
- •Famciclovir and penciclovir
- •Foscarnet
- •Bleomycin
- •Podophyllin resin and podophyllotoxin
- •Cantharidin
- •Sinecatechins
- •5-Fluorouracil and imiquimod (discussed in section 2.5)
- •I. Azoles
- •Itraconazole
- •Fluconazole
- •Ketoconazole
- •Voriconazole
- •Posaconazole
- •Miconazole, clotrimazole, and econazole
- •Efnaconazole
- •Luliconazole
- •II. Allylamines/benzylamines
- •Terbinafne
- •Butenafne
- •IV. Ciclopirox olamine
- •VI. Nystatin
- •VIII. Tavaborole
- •Antiparasitic agents (Tables 2.7 and 2.8)
- •2.7 PHOTOTHERAPY
- •UVA modalities
- •Psoralen plus UVA (PUVA)
- •UVA-1 (340–400 nm)
- •UVB modalities
- •Extracorporeal photochemotherapy
- •Photodynamic therapy (PDT)
- •2.8 MISCELLANEOUS AGENTS
- •Sunscreens
- •Topical cosmetic agents
- •Bimatoprost
- •Brimonidine and oxymetazoline
- •Hydroquinone
- •Psychiatric agents
- •Antiandrogens and androgen inhibitors
- •Spironolactone
- •Finasteride and dutasteride
- •Combination oral contraceptive pills
- •Clascoterone
- •Calcipotriene and calcitriol
- •Attenuated androgens
- •Danazol and stanozolol
- •Colchicine
- •Potassium iodide
- •Thalidomide
- •Topical calcineurin inhibitors
- •Pimecrolimus and tacrolimus
- •Intravenous immunoglobulin (IVIG)
- •Glycopyrrolate
- •Oxybutynin
- •Botulinum toxin
- •Aluminum chloride
- •2.9 DRUG INTERACTIONS AND THE CYTOCHROME P-450 SYSTEM
- •Key points
- •CYP1A2
- •CYP2C9
- •CYP2D6
- •CYP3A4 (most relevant to dermatologists)
- •Classic CYP mnemonics
- •2.10 DRUG REACTIONS
- •Urticaria, angioedema, and anaphylaxis
- •Fixed drug eruption/Stevens-Johnson syndrome/toxic epidermal necrolysis
- •Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS)
- •Acute generalized exanthematous pustulosis (AGEP)
- •Photosensitive drug reactions
- •Drug-induced pigmentary changes
- •Bullous drug reactions, lichenoid drug eruptions, drug-induced connective tissue disease
- •Other drug eruptions
- •3 General dermatology
- •3.1 Papulosquamous dermatoses
- •3.2 Eczematous dermatoses
- •3.3 Interface dermatitis
- •Vacuolar interface dermatitis
- •Autoimmune connective tissue disease (AICTD)
- •Erythema multiforme (EM)
- •Stevens-johnson syndrome (SJS), and toxic epidermal necrolysis (TEN, lyell’s syndrome)
- •Pityriasis lichenoides
- •Fixed drug eruption (FDE)
- •Graft- versus- host disease (GVHD)
- •Lichenoid interface dermatitis
- •Lichen planus (LP)
- •Keratosis lichenoides chronica (KLC)
- •Erythema dyschromicum perstans (ashy dermatosis)
- •Lichenoid keratosis (benign lichenoid keratosis [BLK], LP-like keratosis)
- •Lichen nitidus
- •3.4 Blistering diseases
- •Pemphigus disease family
- •Pemphigus vulgaris (PV)
- •Pemphigus foliaceus (PF)
- •Paraneoplastic pemphigus (PNP)/paraneoplastic autoimmune multiorgan syndrome (PAMS)
- •Autoimmune subepidermal blistering diseases
- •Bullous pemphigoid (BP; pemphigoid)
- •Mucous membrane pemphigoid (MMP; cicatricial pemphigoid)
- •Linear IgA bullous dermatosis/chronic bullous disease of childhood (LABD/CBDC)
- •Epidermolysis bullosa acquisita
- •Bullous systemic lupus erythematosus
- •Dermatitis herpetiformis (duhring disease)
- •Inherited blistering diseases
- •Epidermolysis bullosa (see chapter 4)
- •Darier disease (keratosis follicularis)
- •Other blistering diseases
- •Lupus band test (LBT)
- •Lupus erythematosus
- •Chronic cutaneous lupus erythematosus (CCLE)
- •Subacute cutaneous lupus erythematosus
- •Acute cutaneous lupus erythematosus (ACLE)
- •Other rare cutaneous lupus variants
- •Systemic lupus erythematosus (SLE)
- •Drug-induced SLE (DI-SLE)
- •Lupus-related diseases
- •Other autoimmune connective tissue diseases and sclerosing dermopathies
- •Dermatomyositis (DM)
- •Sjögren’s syndrome
- •Relapsing polychondritis
- •Mixed connective tissue disease (MCTD)
- •Rheumatoid arthritis
- •Systemic-onset juvenile idiopathic arthritis (still’s disease)
- •Morphea (localized scleroderma)
- •Eosinophilic fasciitis (shulman syndrome)
- •Abnormalities of connective tissue
- •3.6 Granulomatous/histiocytic disorders
- •Non-infectious granulomas
- •Granuloma annulare (GA)
- •Annular elastolytic giant cell granuloma (actinic granuloma of O’Brien
- •Interstitial granulomatous dermatitis and arthritis (IGDA) and palisaded neutrophilic granulomatous dermatitis (PNGD)
- •Interstitial granulomatous drug eruption
- •Necrobiosis lipoidica (necrobiosis lipoidica diabeticorum, NLD)
- •Necrobiotic xanthogranuloma (NXG)
- •Cutaneous crohn’s disease
- •Sarcoidosis
- •Histiocytoses
- •Langerhans cell histiocytosis (LCH)
- •Non-langerhans cell histiocytoses (discussed in Table 3.23)
- •Malignant histiocytic disorders
- •3.7 Monoclonal gammopathies of dermatologic interest
- •3.8 Xanthomas
- •3.9 Urticaria and angioedema
- •3.10 Neutrophilic dermatoses
- •Amicrobial pustulosis of the folds
- •3.11 Eosinophilic disorders
- •Granuloma faciale
- •Eosinophilic folliculitis
- •Papuloerythroderma of ofuji
- •Wells’ syndrome (eosinophilic cellulitis)
- •Hypereosinophilic syndrome (HES)
- •3.12 Figurate erythemas
- •3.13 Follicular and eccrine/apocrine disorders
- •Acne variants
- •Acne fulminans
- •Acne conglobata
- •Solid facial edema in acne
- •Acne mechanica
- •Neonatal acne (neonatal cephalic pustulosis)
- •Infantile acne
- •Transverse nasal crease
- •Acne in setting of endocrinologic abnormality
- •Acne cosmetica
- •Pomade acne
- •Chloracne
- •Radiation acne
- •Acneiform eruptions
- •Drug-induced acne
- •Acne-associated syndromes
- •SAPHO (chronic recurrent multifocal osteomyelitis)
- •PAPA
- •HAIR-AN
- •Apert syndrome (acrocephalosyndactyly)
- •Rosacea
- •Epidemiology
- •Rosacea subtypes
- •Erythematotelangiectatic (vascular)
- •Phymatous
- •Ocular
- •Rosacea variants
- •Solid facial edema in rosacea (morbihan disease and rosacea lymphedema)
- •Pyoderma faciale (rosacea fulminans)
- •Granulomatous rosacea
- •Lupus miliaris disseminatus faciei
- •Folliculitis
- •Gram-negative folliculitis
- •Hot tub folliculitis
- •Eosinophilic folliculitis
- •Disseminate and recurrent infundibulofolliculitis
- •Viral-associated trichodysplasia
- •Pseudofolliculitis barbae
- •Acne keloidalis nuchae
- •Follicular occlusion tetrad (acne conglobata, hidradenitis suppurativa, dissecting cellulitis of the scalp, and pilonidal cyst)
- •Hidradenitis suppurativa (acne inversa)
- •Pilonidal cyst
- •Dissecting cellulitis of the scalp and acne conglobata (discussed in alopecia and acne sections)
- •Other diseases of eccrine and apocrine sweat glands
- •Hyperhidrosis
- •Hypohidrosis and anhidrosis
- •Miliaria
- •Bromhidrosis
- •Chromhidrosis
- •Fox-fordyce disease (apocrine miliaria)
- •3.14 Drug reactions
- •3.15 Photodermatoses and other physical dermatoses
- •Temperature-related dermatoses
- •Thermal burns
- •Erythema ab igne
- •Cold injuries
- •Photoaging
- •Polymorphous light eruption
- •Hydroa vacciniforme (see Chapter 4)
- •Actinic folliculitis
- •Chronic actinic dermatitis
- •Actinic prurigo (see chapter 4)
- •Solar urticaria
- •Mechanical injuries
- •3.17 Neurodermatology and psychodermatology
- •Cutaneous manifestations of psychiatric illness or self-induction
- •Delusions of parasitosis
- •Excoriation disorder (neurotic excoriations)
- •Factitial dermatitis/dermatitis artefacta
- •Gardner-diamond syndrome
- •Body dysmorphic disorder
- •Cupping/coining
- •Other neurocutaneous dermatoses
- •Scalp dysesthesia/burning scalp syndrome
- •Burning mouth syndrome
- •Brachioradial pruritus
- •Notalgia paresthetica
- •Meralgia paresthetica
- •Trigeminal trophic syndrome
- •Familial dysautonomia/riley-day syndrome
- •Auriculotemporal nerve syndrome (frey syndrome)
- •3.18 Palmoplantar keratodermas
- •3.19 Nutritional disorders in dermatology
- •3.21 Ulcers (Table 3.33)
- •3.22 Vasculitides, vasculopathies, and other vascular disorders
- •Subtypes of cutaneous small vessel vasculitis
- •Henoch-schonlein purpura (HSP)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Key features of adult HSP
- •Key features of childhood HSP
- •Treatment
- •Laboratory testing: See CSVV section
- •Pathology
- •Acute hemorrhagic edema of infancy (Fig 3.86)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Treatment
- •Urticarial vasculitis
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Laboratory testing
- •Treatment (Table 3.41)
- •Erythema elevatum diutinum
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Treatment
- •Mixed cryoglobulinemia (see cryoglobulinemia section)
- •Small to medium vessel vasculitis
- •Granulomatosis with polyangiitis (wegener)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Treatment
- •Microscopic polyangiitis (MPA)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Laboratory testing: See CSVV, especially:
- •Treatment
- •Eosinophilic granulomatosis with polyangiitis (churg-strauss syndrome)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation: Three classic stages (Table 3.47)
- •Pathology
- •Laboratory testing
- •Treatment
- •Medium vessel vasculitis
- •Subtypes: PAN and kawasaki’s disease
- •Polyarteritis nodosa
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Laboratory testing: See CSVV
- •Treatment
- •Kawasaki disease (acute febrile mucocutaneous lymph node syndrome)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation (Fig. 3.90)
- •Laboratory testing
- •Treatment
- •Key testing facts
- •Large vessel vasculitis
- •Subtypes: Temporal arteritis and Takayasu’s arteritis
- •Temporal arteritis (giant cell arteritis)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Laboratory workup
- •Treatment
- •Takayasu’s arteritis
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Laboratory workup
- •Treatment
- •Summary of organ system involvement in various vasculitides (Table 3.49)
- •Cryoglobulinemias
- •Epidemiology
- •Thrombosis and thrombotic syndromes
- •Important subtypes
- •Calciphylaxis
- •Antiphospholipid syndrome
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Treatment
- •Pathogenesis
- •Clinical presentation
- •Pathology
- •Treatment
- •Other vasculopathies (Table 3.51)
- •Other vascular disorders
- •Venous lake
- •Telangiectasia
- •Erythromelalgia
- •Livedo reticularis (LR)
- •Angiospastic macules (bier spots)
- •3.23 Panniculitides and lipodystrophies
- •3.24 Dermatoses of pregnancy
- •3.25 Hair, nail, and mucosal disorders
- •Non-scarring alopecia
- •Androgenetic alopecia
- •Trichotillomania
- •Alopecia areata
- •Temporal triangular alopecia
- •Congenital atrichia with papules
- •Cicatricial (scarring) alopecia
- •Central centrifugal cicatricial alopecia
- •Lichen planopilaris
- •Acne keloidalis nuchae
- •Dissecting cellulitis of the scalp (perifolliculitis capitis abscedens et suffodiens)
- •Folliculitis decalvans
- •Traction alopecia
- •Hair shaft abnormalities
- •Hypertrichosis and hirsutism
- •Hypertrichosis
- •Nail disorders
- •Mucosal disorders
- •3.26 Pigmentary disorders
- •Disorders of hypopigmentation and depigmentation
- •Vitiligo
- •Halo nevus
- •Chemical and physical agent-induced hypopigmentation
- •Idiopathic guttate hypomelanosis
- •Progressive macular hypomelanosis
- •Nevus anemicus
- •Pigmentary mosaicism
- •Hypomelanosis of ito
- •Nevus depigmentosus
- •Disorders of hyperpigmentation
- •Melasma
- •Erythema dyschromicum perstans (ashy dermatosis) discussed in Section 3.3
- •Lichen planus pigmentosus
- •Linear and whorled nevoid hypermelanosis
- •Prurigo pigmentosa
- •Familial progressive hyperpigmentation
- •Endocrinopathies
- •Pigmentary demarcation lines (aka futcher’s lines, voight lines, ito’s lines)
- •4 Pediatric dermatology
- •4.1 Neonatal dermatology
- •4.2 Viral exanthems and select infectious disorders of childhood
- •4.3 Inherited pigmentary disorders
- •Hypo-/depigmentation
- •Pigmentary mosaicism
- •Oculocutaneous albinism (OCA)
- •Silvery hair syndromes
- •Griscelli syndrome
- •Hermansky-Pudlak syndrome
- •Piebaldism
- •Waardenburg syndrome
- •Hyperpigmentation
- •McCune-Albright syndrome
- •Lentiginoses syndromes
- •Hereditary dyschromatoses
- •Dyschromatosis symmetrica hereditaria (acropigmentation of Dohi)
- •Dyschromatosis universalis hereditaria
- •Naegeli-Franceschetti-Jadassohn syndrome (NFJS)/dermatopathia pigmentosa reticularis (DPR)
- •4.4 Epidermolysis bullosa
- •4.5 Tumor syndromes
- •4.6 Vascular tumors, malformations, and related vascular disorders
- •Vascular tumors
- •Phace syndrome
- •LUMBAR/SACRAL syndrome
- •Multiple hemangiomas
- •Kasabach-Merritt phenomenon
- •Vascular malformations
- •Capillary malformations (CM)
- •Sturge-Weber syndrome (encephalotrigeminal angiomatosis)
- •Phakomatosis pigmentovascularis
- •Phakomatosis pigmentokeratotica
- •PIK3CA-related overgrowth spectrum (PROS)
- •Klippel-trenaunay syndrome
- •Macrocephaly capillary malformation syndrome
- •Cloves syndrome
- •Proteus syndrome
- •Beckwith-wiedemann syndrome
- •Diffuse capillary malformation with overgrowth (DCMO)
- •Venous malformations
- •Maffucci syndrome (enchondromas with multiple angiomas)
- •Blue rubber bleb nevus syndrome
- •Glomulovenous malformations (GVMs; previously termed “glomangiomas”)
- •Lymphatic malformations
- •Macrocystic lymphatic malformations (cystic hygroma)
- •Gorham-stout (disappearing bone) disease
- •Congenital lymphedema (hereditary congenital lymphedema, Nonne-Milroy syndrome)
- •Arteriovenous malformations
- •AVMs
- •Parkes-weber syndrome
- •Cobb syndrome (cutaneomeningospinal angiomatosis)
- •Other vascular disorders
- •4.7 Disorders of hair and nails
- •Pachyonychia congenita
- •Ectodermal dysplasias
- •Hypohidrotic ectodermal dysplasia (Christ-Siemens-Touraine syndrome)
- •Hidrotic ectodermal dysplasia (Clouston syndrome)
- •Ectodermal dysplasias due to p63 mutation
- •Schöpf-Schulz-Passarge syndrome
- •Other disorders
- •Rubinstein-Taybi syndrome
- •Parakeratosis pustulosa
- •Congenital malalignment of the great toenails
- •4.8 Inherited metabolic and nutritional disorders
- •4.9 Inherited connective tissue disorders
- •4.10 Autoinflammatory disorders (periodic fever syndromes)
- •4.12 Premature aging syndromes and DNA repair disorders
- •4.13 Primary immunodeficiency disorders with cutaneous manifestations
- •4.14 Disorders of cornification
- •Actinic prurigo
- •Diaper dermatitis
- •Juvenile plantar dermatosis
- •Acropustulosis of infancy
- •Trichorhinophalangeal syndrome
- •Midas syndrome (also MLS or microphthalmia with linear skin defects)
- •H syndrome
- •Cutaneous mastocytosis
- •Neutrophilic eccrine hidradenitis of childhood
- •5 Infectious diseases
- •5.1 Viral diseases
- •Herpes simplex virus (HHV-1/HSV-1 and HHV-2/HSV-2)
- •Varicella zoster virus (VZV; HHV-3)
- •Epstein-Barr virus (HHV-4)
- •Cytomegalovirus (HHV-5)
- •HHV-6 (Roseola infantum, exanthem subitum, sixth disease)
- •HHV-7
- •HHV-8
- •Poxviruses
- •Zika virus
- •Dengue virus
- •Viral hepatitides (Table 5.2)
- •Viral-associated trichodysplasia of immunosuppression
- •COVID-19
- •5.2 HIV/AIDS dermatology
- •5.3 Bacterial infections
- •Staphylococcal skin infections
- •Corynebacterial skin infections
- •Clostridium skin infections
- •Filamentous bacteria
- •Other gram-positive infections
- •Pseudomonas
- •Bartonella
- •Rickettsia
- •Other gram-negative skin infections
- •Borrelia
- •Nonvenereal (endemic) treponematoses
- •Syphilis
- •Cutaneous tuberculosis
- •Leprosy (hansen’s disease)
- •Atypical mycobacteria
- •Tinea versicolor (pityriasis versicolor)
- •Piedra
- •Tinea nigra
- •Sporotrichosis
- •Lobomycosis
- •Mycetoma (madura foot)
- •Chromoblastomycosis
- •Histoplasmosis
- •Blastomycosis (“north American blastomycosis”)
- •Coccidioidomycosis
- •Paracoccidioidomycosis (“South American blastomycosis”)
- •Candidiasis
- •Cryptococcosis
- •Aspergillosis
- •Fusarium
- •Penicilliosis
- •Zygomycosis (mucormycosis)
- •Phaeohyphomycosis
- •Protothecosis
- •Rhinosporidiosis
- •5.5 Parasites and other creatures
- •Parasitic infestations
- •Scabies
- •Lice
- •Tungiasis
- •Myiasis
- •Protozoa
- •Leishmaniasis
- •Toxoplasmosis
- •Helminths
- •Cutaneous larva migrans
- •Larva currens
- •Onchocerciasis (“river blindness”)
- •Loiasis
- •Filariasis
- •Swimmer’s itch and seabather’s eruption
- •Trichinosis
- •Dracunculiasis (guinea worm)
- •Gnathosomiasis
- •Cysticercosis
- •Cutaneous amebiasis
- •Free-living amoeba
- •Gi-associated amoeba
- •Bites and stings
- •Biting and stinging insects
- •Arachnids (ticks, mites, spiders, and scorpions)
- •Millipedes and centipedes
- •Snake bites
- •6 Neoplastic dermatology
- •Neoplastic dermatology
- •6.1 Keratinocytic neoplasms
- •Premalignant/malignant
- •Actinic keratosis (AK)
- •Bowen’s disease (squamous cell carcinoma in situ)
- •Invasive cutaneous squamous cell carcinoma (cSCC, “SCC”)
- •Verrucous carcinoma
- •Keratoacanthoma
- •Basal cell carcinoma
- •6.2 Cysts
- •6.3 Melanocytic neoplasms
- •6.4 Adnexal neoplasms and hamartomas
- •Comparative dermatopathologic features of sweat gland neoplasms for board exam purposes
- •Poroma (classic juxtaepidermal type)
- •Hidroacanthoma simplex
- •Dermal duct tumor
- •Hidradenoma
- •Spiradenoma
- •Cylindroma
- •Syringoma
- •Mixed tumor (MT; “chondroid syringoma”)
- •Hidradenoma papilliferum (HPAP)
- •Syringocystadenoma papilliferum (SPAP, SCAP)
- •Papillary eccrine adenoma (PEA)
- •Tubular apocrine adenoma (TAA)
- •Porokeratotic eccrine ostial and dermal duct nevus
- •Microcystic adnexal carcinoma (MAC)
- •Aggressive digital papillary adenocarcinoma (ADPA)
- •Adenoid cystic carcinoma (ACC)
- •6.5 Hair follicle neoplasms/hamartomas
- •Folliculo-sebaceous-apocrine hamartomas
- •Trichofolliculoma
- •Fibrofolliculoma
- •Nevus sebaceus
- •Neoplasms with follicular germinative differentiation
- •Trichoepithelioma
- •Neoplasms with follicular matrix differentiation
- •Pilomatricoma (calcifying epithelioma of malherbe)
- •Neoplasms with follicular sheath (trichilemmal) differentiation
- •Trichilemmoma
- •Desmoplastic trichilemmoma (DTL)
- •Tumor of the follicular infundibulum (TFI)
- •Trichoadenoma (TA; of Nikolowski)
- •Proliferating pilar (trichilemmal) tumor
- •6.6 Sebaceous proliferations
- •6.7 Neural neoplasms
- •6.8 Smooth muscle neoplasms
- •6.9 Hematolymphoid neoplasms
- •6.10 Fibrohistiocytic neoplasms
- •Multinucleate cell angiohistiocytoma
- •Nodular fasciitis
- •Fibrous hamartoma of infancy
- •Giant cell tumor of tendon sheath (tenosynovial giant cell tumor)
- •Connective tissue nevus (collagenoma and elastoma)
- •6.11 Vascular proliferations
- •Benign vascular lesions
- •Vascular malformation (includes “port wine stain,” “cavernous hemangioma” old terminology)
- •Intravascular papillary endothelial hyperplasia (masson tumor, pseudoangiosarcoma)
- •Angiokeratoma
- •Infantile hemangioma
- •Pyogenic granuloma (lobular capillary hemangioma)
- •Epithelioid hemangioma (angiolymphoid hyperplasia with eosinophils, ALHE)
- •Targetoid hemosiderotic lymphatic malformation (hobnail hemangioma, targetoid hemosiderotic hemangioma)
- •Tufted angioma
- •Glomeruloid hemangioma
- •Glomus tumor/glomangioma
- •Borderline vascular neoplasms
- •Kaposiform hemangioendothelioma
- •Kaposi sarcoma (KS)
- •Other borderline vascular neoplasms (rare; not commonly tested)
- •High-grade malignant vascular neoplasms
- •Angiosarcoma
- •Vascular neoplasm associations
- •6.12 Neoplasms of adipocytic lineage
- •6.13 Dermoscopy
- •Seborrheic keratosis
- •Actinic keratosis
- •Basal cell carcinoma
- •Squamous cell carcinoma in situ
- •Squamous cell carcinoma
- •Ink spot lentigo
- •Vascular lesions (e.g., cherry angiomas)
- •Hemorrhage
- •Porokeratosis
- •Sebaceous hyperplasia
- •Dermoscopic patterns of melanocytic lesions
- •7 Dermatopathology
- •7.1 Essential concepts in dermatopathology
- •7.2 High-yield dermatopathology diagnoses at a glance
- •7.3 High-yield dermatopathology differential diagnoses
- •8 Dermatologic surgery
- •8.1 Surgical anatomy
- •8.2 Local anesthetics and perioperative pain control
- •8.3 Surgical instruments and needles
- •8.4 Suture techniques
- •8.5 Wound closure materials
- •8.7 Electrosurgery
- •8.8 Cryosurgery
- •8.9 Excisions
- •8.10 Mohs surgery
- •8.11 Flaps
- •8.12 Grafts
- •8.13 Surgical complications and measures to avoid them
- •8.14 Scar improvement
- •8.15 Nail surgery
- •8.16 Wound dressings
- •9 Cosmetic dermatology
- •9.1 Lasers

Table 8.1 Sensory Innervation of Head and Neck
Nerve Innervation Comments
Trigeminal nerve
Ophthalmic (V1; has 3 major
branches)
Maxillary (V2) Zygomaticotemporal nerve (temple and temporal scalp)
Mandibular (V3) Auriculotemporal nerve ( superior portion of anterior
Cervical nerves
Lesser occipital (C2) Postauricular neck/scalp —
Greater occipital (C2) Occipital scalp (majority) —
Great auricular (C2, C3) Infra-auricular neck, mandibular angle, majority of
Transverse cervical (C2, C3) Anterior and lateral neck —
Supraclavicular (C3, C4) Supraclavicular and infraclavicular fossa, upper chest,
Frontal nerve (2 divisions)
Supraorbital (upper eyelid, forehead, and frontal to ver-
tex scalp)
Supratrochlear (medial upper eyelid, medial forehead,
and medial frontal scalp)
Nasociliary nerve (3 important divisions)
Infratrochlear (nasal root, medial canthus)
Anterior ethmoidal (distal/inferior half of central
nose: dorsum, supratip, tip, and columella)
Ciliary (cornea)
Lacrimal nerve: lateral eyelid, conjunctiva, and lacrimal
gland
Zygomaticofacial nerve (malar cheek)
Infraorbital nerve (medial cheek, lower eyelid, nasal
sidewall, nasal ala, upper lip, upper teeth, and
maxillary gingiva)
external ear and auditory canal, temple, temporoparietal scalp, TMJ, outer aspect of tympanic membrane,
and parasympathetic innervation of parotid)
Buccal nerve (buccal mucosa, angle of mouth, and
gingiva)
Mental nerve (lower lip and chin)
Lingual nerve (sensation to anterior 2/3 of tongue)
external ear (both anterior and posterior portions,
including earlobe), and postauricular scalp
shoulder
Supraorbital nerve danger zone: nerve courses supercially at
vertical distances above the palpable orbital rim of 1.3 cm or
greater → nerve easily injured during a deep shave, punch
or ED&C of lower to midforehead → paresthesia, traumatic
neuroma
Supraorbital and supratrochlear nerves are commonly anesthe-
tized via nerve block
Hutchinson’s sign: involvement of nasociliary branch by VZV
(distal nasal vesicles, ulcers) is almost always a/w herpes zos-
ter ophthalmicus; conversely, it is very rare to have ocular involvement in absence of distal nasal skin lesions!
Infraorbital nerve is commonly anesthetized via nerve block
Auriculotemporal nerve is frequently injured during TMJ
surgery (→ paresthesia of ear and temple) and parotidectomy (→ injured parasympathetic nerves erroneously reattach
to sweat glands in area → Frey syndrome)
Mental nerve is commonly anesthetized via nerve block
Mandibular nerve (V3) also provides motor innervation to
muscles of mastication (masseter, medial and lateral pterygoid, temporalis)
8.1 Surgical Anatomy
Table 8.2 Other High-Yield Sensory Nerve Innervation Facts
Site Nerves and Innervation Comments
Ear In decreasing order of area:
Great auricular: majority of posterior ear and 3/4 of ante-
rior ear (all except quadrant innervated by auriculotemporal and area innervated by cranial nerves)
Auriculotemporal: entire “anterior-superior quadrant” of
ear (excluding conchal bowl, but including EAM), and
superior portion of posterior helix
Cranial nerves VII, IX, and X: Conchal bowl and EAM
(most important!), also contributes to posterior notch
innervation
Lesser occipital: posterior notch
Hand Median, radial, and ulnar Opposing the thumb and fth nger makes the palmaris longus tendon
Ring block around ear anesthetizes everything (except conchal bowl and
EAM 5 supplied by CN7, CN9, CN10)
apparent; typically use 3–5 mL of anesthetic
Median nerve block: inject at proximal wrist crease, between palmaris longus
and exor carpi radialis tendons (i.e., inject radial to palmaris longus ten-
don at proximal wrist crease)
Ulnar nerve block: inject immediately radial to exor carpi ulnaris at proxi-
mal wrist crease
Radial nerve block: inject along the proximal wrist crease, starting immedi-
ately lateral to radial artery, extending all the way to dorsal midwrist
Continued
445

CHAPTER 8 • Dermatologic Surgery
Table 8.2 Other High-Yield Sensory Nerve Innervation Facts—cont'd
Site Nerves and Innervation Comments
Foot Posterior tibial, saphenous, sural, superficial peroneal, and
Fingers,
toes
Tongue Taste: CN VII (chorda tympani branch; anterior 2/3)
Penis Dorsal nerve of penis bifurcates into major anterior (dorsal) and
EAM, External acoustic meatus; MCP, metacarpophalangeal; MTP, metatarsophalangeal; PVD, peripheral vascular disease.
deep peroneal
Two dorsal and two ventral nerves per digit Multiple ways to perform digital block
Sensory: CN V3 (lingual nerve; anterior 2/3)
Glossopharyngeal (CN IX) provides both taste and somatic
sensation to posterior 1/3
minor posterior (ventral) branches at the base of the penis
Sites for foot block are highly testable!
Posterior tibial nerve: inject in groove between medial malleolus and
Achilles tendon; nerve is posterior to posterior tibial artery
Sural nerve: inject in groove between lateral malleolus and Achilles tendon
Deep peroneal: inject lateral to hallucis longus tendon → down to bone
(though block rarely needed as local inltration between rst and second toe
adequate)
Saphenous and supercial peroneal: inject on dorsal foot, subcutaneously,
from malleolus to malleolus
Classic technique: inject immediately distal MCP/MTP, using 1–2 mL on each
side (2–4 mL total per digit); do NOT exceed 8 mL per digit (risk of tourni-
quet effect)
Safe to use lidocaine w/ epinephrine, unless patient has underlying PVD
Motor innervation of tongue: predominantly CN XII (hypoglossal nerve)
Injecting a ring of lidocaine around the base of penis anesthetizes almost entire
penis except periurethral glans
Supraorbital nerve (lateral branch)
Supraorbital nerve (medial branch)
Supratrochlear nerve
Infratrochlear nerve
Lacrimal nerve
External nasal branch
(anterior ethmoidal nerve)
Maxillary nerve (V2)
Zygomaticotemporal nerve
Zygomaticofacial nerve
Infraorbital nerve
Auriculotemporal nerve
Buccal nerve
Mental nerve
Lesser occipital
nerve (C2)
Great auricular
nerve (C2, C3)
Transverse cervical
nerve (C2, C3)
Fig. 8.2 Trigeminal (cranial nerve V) and cervical plexus sensory nerves. (From Salasche SJ, Mandy SH. Anatomy. In: Rohrer TE, Cook JL, Kaufman AJ, eds. Flaps and
Grafts in Dermatologic Surgery. 2nd ed. Philadelphia: Elsevier; 2018:1–15.)
446

Superficial
peroneal nerve
Sural nerve
8.1 Surgical Anatomy
Saphenous nerve
Deep peroneal nerve
Posterior tibial nerve
Saphenous nerve
Sural nerve
Fig. 8.3 Sensory innervation of the foot. (From Soriano TT, Breithaupt A, Chesnut C. Anesthesia and analgesia. In: Robinson JK, Hanke CW, Siegel DM, Fratila A, eds.
Surgery of the Skin. 3rd ed. Philadelphia, Elsevier, 2015:43–63.)
SENSORY INNERVATION OF THE HAND
R
U
M
R
U
M
M Median nerve
R Radial nerve
U Ulnar nerve
Fig. 8.4 Sensory innervation of the palmar and dorsal surface of the right hand. (From Hruza GJ. Anesthesia. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology.
4th ed. Philadelphia: Elsevier; 2018:2440–2449.)
447

CHAPTER 8 • Dermatologic Surgery
Table 8.3 Motor Innervation of the Head and Neck
Facial Nerve (CN VII) Branch Muscles Innervated and Normal Function Nerve Injury-Related Findings Other Comments
Temporal Frontalis (eyebrow elevation)
Corrugator supercilii (pulls eyebrows infero-
medially)
Upper orbicularis oculi (tight closure of eyelids,
blinking)
Zygomatic Orbicularis oculi (lower portion)
Procerus (pull eyebrows down, “horizontal
glabellar lines”)
Nasalis (transverse—wrinkle nose; alar—ares
nostrils)
Lip elevators:
Levator labii superioris alaeque nasi (ares
nostril and elevates upper lip)
Levator labii superioris (elevates and everts
upper lip)
Zygomaticus major and minor (mouth angle
retractors/elevators, main muscles responsible for smiling)
Buccal Buccinator (attens cheeks against teeth w/
help of orbicularis oris → prevents food accumulation; high-pressure blowing)
Orbicularis oris (pursing/puckering of lips, ap-
position of corners of mouth, pulls lips tight up
against teeth, and is required for clear speech)
Depressor septi nasi (pulls columella toward lip)
Lip elevators:
Levator labii superioris alaeque nasi, levator labii
superioris, zygomaticus major and minor (variable innervation from zygomatic and buccal)
Levator anguli oris (mouth angle retractor/
elevator)
Risorius (mouth angle retractor, lesser role in
smiling)
Marginal mandibular Orbicularis oris
Lip depressors:
Depressor anguli oris (lip depressor/retractor)
Depressor labii inferioris (lip depressor/retractor)
Mentalis (lower lip protrusion and elevation)
Upper platysma (intercalates with lip depres-
sors/retractors)
Cervical Platysma (tenses neck skin, intercalates w/ lip
depressors)
Inability to elevate eyebrows
→ eyebrow ptosis
Inability to shut eyes (1/–
lower lid ectropion), flare
nostrils, and elevate upper
lip
Food accumulation between
cheek and teeth
Inability to pucker/purse lips
Drooling as a result of ↓ lip seal-
ing ability
Speech is mufed, cannot
enunciate letters M, V, F, P,
and O
Uneven facial expression at
rest and w/ smiling (zygo-
matic 1 buccal) vs. only
upon smiling with marginal
mandibular
Face appears normal at rest but
asymmetric when smiling
Drooling
Inability to evert lower lip
↓ Ability to grimace
Targets for Botox:
Frontalis (horizontal forehead
wrinkles)
Orbicularis (“crow’s feet”)
Corrugator supercilii (vertical
glabellar lines, scowling
appearance)
Zygomatic and buccal
branches have extensive
cross innervation (esp. to na-
salis muscle and lip elevators)
Targets for Botox:
Procerus (“horizontal glabellar
lines”)
Nasalis (“bunny lines” and ared
nostrils)
Levator labii superioris (“gummy
smile”)
Zygomatic and buccal branches
have numerous rami and
extensive cross innervation, so
deficits are often partial and
temporary unless extensive
damage
Marginal mandibular is at highest
risk of causing permanent
motor decits because has
only 1–2 rami and is covered by
thin skin and thin platysma
Can be injured during neck lipo-
suction or submentoplasty
Botox can be used to target
platysma (“platysmal bands”)
Table 8.4 Cutaneous Danger Zones
Target Structure Danger Zone Associated Adverse Event Other Comments
Vascular occlusion from ller/steroid injections
Angular artery Near base of ala Skin necrosis Rx: nitroglycerin paste, LMWH, and
Supratrochlear artery Glabellar region Skin necrosis, blindness Same as above
Motor nerve injury
Temporal nerve Most susceptible to injury as it
Zygomatic and buccal nerves (less
common)
crosses over the zygomatic
arch
Most significant deficits (i.e., proximal
nerve injuries) occur lateral to an
imaginary line drawn from lateral
canthus to oral commissure
Unilateral frontalis paralysis,
eyebrow ptosis
Variable depending on extent of
damage (see Table 8.4)
hyaluronidase (if HA filler)
Temporal nerve runs a diagonal course
from 0.5 cm below the tragus to
1.5 cm above the lateral brow; nerve
is supercially located within the fascia
as it crosses the zygomatic arch
Rx: eyebrow lift
Main trunks of zygomatic and buccal
branches of facial nerve lie fairly deep
→ injuries are uncommon
448

8.1 Surgical Anatomy
Table 8.4 Cutaneous Danger Zones—cont'd
Target Structure Danger Zone Associated Adverse Event Other Comments
Marginal mandibular nerve Most susceptible 2–3 cm
Spinal accessory nerve (cranial
nerve XI)
Ulnar nerve Susceptible to injury around medial
Other
Parotid duct A line drawn from tragus to mid
HA, Hyaluronic acid; LMWH, low-molecular-weight heparin; SCM, sternocleidomastoid muscle.
inferolateral to oral commissure,
as it passes over the mandible
(anterior to facial artery)
Most susceptible to injury at Erb’s
point 5 site where cervical plexus
emerges; located along posterior
border of SCM
epicondyle of humerus
portion of the upper lip approximates
its course; duct courses over
masseter, pierces buccinator, and
drains into the oral vestibule next to
second upper molar
Branches of facial nerve and danger zones for undermining
Facial asymmetry upon smiling
(normal at rest), inability to
protrude lower lip, and drooling
Winged scapula, inability to
abduct arm, and shoulder pain
“Claw-hand” deformity; weakness
in wrist flexion; loss of sensation
and flexion of fourth and fifth digits
Parotid duct fistula; sialocele
(distinguished from a seroma by
hh
amylase levels)
Nerve runs along angle and inferior
border of mandible, passing
superficially over facial artery
Erb’s point localization: 6 cm inferior
to the midpoint of an imaginary line
drawn between the mastoid process
and angle of jaw
Great auricular and lesser occipital
nerves also emanate from Erb’s point
Rx: repair via microsurgery
Frontalis muscle
Temporal branches
Whitnall's tubercle
Zygomatic branches
Buccal branches
Marginal mandibular branch
= Danger zones for undermining
Cervical branch
Parotid gland
Fig. 8.5 Branches of the facial nerve and danger
zones. (From Robinson JK. Anatomy for procedural
dermatology. In: Robinson JK, Hanke CW, Siegel
DM, Fratila A, eds. Surgery of the Skin. 3rd ed. Phila-
delphia: Elsevier; 2015:1–27.)
449

CHAPTER 8 • Dermatologic Surgery
8.2 LOCAL ANESTHETICS AND PERIOPERATIVE PAIN CONTROL
• Three major categories of afferent sensory bers:
■
C bers: small diameter, unmyelinated nociceptors;
transmit diffuse, dull, aching pain
■
Ad bers: medium diameter, lightly myelinated bers;
transmit sharp, localized pain and temperature
■
Ab bers: fast-conducting, large-diameter, myelinated
bers; detect vibration and light pressure; large Ab
bers respond slowly to local anesthetic → patients
continue to “feel something, but not pain” after
injection
• Local anesthetics (Table 8.5)
■
Mechanism: reversible inhibition of sodium ion
inux → prevents depolarization → blocks nerve
conduction
■
Chemical structure
Aromatic end—lipophilic, affects potency (more
lipid soluble → more potent) and duration (more
lipid soluble → longer duration because re-lingers
longer in tissues)
♦ Clinical factoid: Bupivicaine is more lipid soluble
than Lidocaine →
Intermediate chain—linkage portion
♦ Amides (most commonly used)
Metabolized via CYP 3A4 in liver
Esters versus amides: “two ‘I’s’ 5 amIde”
Allergic reactions: very rare and typically result
from methylparaben or sodium metabisulte
preservatives, not the anesthetic; if allergy
exists, switch to preservative-free lidocaine
Caution: end-stage liver disease
♦ Esters
Metabolized via pseudocholinesterases in
plasma; renally excreted
Less stable in solution
Frequent allergic reactions to PABA metabolite
Cross-reacts with multiple contact allergens
(Mnemonic “PPPESTAA”):
Paraphenylenediamine (PPD), PABA, Para-
aminosalicylic acid, Ethylenediamine,
Sulfonamides, Thiazides, Anesthetics
(esters), Azo dyes
Contraindications: allergy to PABA or cross-
reactors, pseudocholinesterase deciency
Caution: renal insufciency
Amine end—hydrophilic, binds sodium channel,
and determines onset of action; more rapid onset
when amine group is unprotonated vs. protonated
Table 8.5 Testable Facts Regarding Specic Anesthetics
Anesthetic
Amides
Lidocaine
(Xylocaine)
Prilocaine B 5–6 30–120 60–400 7 mg/10 mg Risk of methemoglobinemia
Etidocaine B 3–5 200 240–360 4.5 mg/6.5 mg —
Ropivicaine B 1–15 120–360 Same as w/o epi 3.5 mg/NA Longest duration of action in
Mepivacaine C 3–20 30–120 60–400 6 mg/8 mg Slowest onset of action
Bupivicaine
(Marcaine)
Esters
Procaine
(Novocaine)
Chloroprocaine C 5–6 30–60 Not known 10 mg/NA —
Tetracaine C 7 120–240 240–480 2 mg/2 mg —
EMLA, Eutectic Mixture of Local Anesthesia.
Modied from Soriano TT, Breithaupt A, Chesnut C. Anesthesia and analgesia. Robinson JK, Hanke CW, Siegel DM, Fratila A, eds. Surgery of the Skin. 3rd ed.
Philadelphia: Elsevier; 2015:43–63.
Pregnancy
Category
B
C 2–10 120–240 240–480 2.5 mg/3 mg Longest duration of action when
C 5 15–30 30–90 10 mg/14 mg Shortest duration of action
Onset
(min)
,1
Duration w/o epi
(min)
30–120 60–400 4.5 mg/7 mg
Duration w/ epi
(min)
Max Adult Dose
(mg/kg) wo/w epi Most Important Points
(safe to use up
to 55 mg/kg
w/ tumescent
anesthesia)
Fastest onset of action (,1 min)
Anesthetic of choice in
pregnant women
(↑ risk w/ G6PD deficiency and in
children , 1 yo)
Component of topical EMLA
absence of epinephrine (up to
6 hours)
Risk of fetal bradycardia
combined w/ epinephrine (up to
8 hours)
Most common use: added to
lidocaine for cases requiring
prolonged anesthesia
Highest risk of cardiac toxicity!
Risk of fetal bradycardia
450

8.2 Local Anesthetics and Perioperative Pain Control
→ alkalinization with bicarbonate speeds onset by
decreasing proportion of positively charged/
protonated amine groups
■
Additives to local anesthetics
Epinephrine (1:200,000 equally as effective, w/
↓ toxicity than 1:100,000)
♦ Mechanism: vasoconstriction → localization of
anesthetic
♦ Advantages: ↑ safety and duration of anesthetic
(because less diffusion and absorption), ↓ bleeding
(full vasoconstriction takes 7–15 minutes)
♦ Disadvantages: ↓ uterine blood ow (pregnancy
category C)
♦ Contraindications: pheochromocytoma,
uncontrolled HTN, digital anesthesia in severe
PVD, and uncontrolled hyperthyroidism
♦ Caution: pregnancy (diluting to 1:300,000
angle glaucoma (periorbital injection), and
drugs (nonselective b-blockers, TCAs, and
MAO-I)
♦ Lidocaine with epinephrine is manufactured to
be more acidic (pH 4) than Plain lidocaine (pH
6) because the acidic environment prolongs
Epinephrine shelf-life → Lidocaine + Epi is more
painful ("burns like acid because it is acid!")
than Plain Lidocaine
Sodium bicarbonate 8.4% (1 mL per 10 mL of 1%
lidocaine)
♦ Mechanism: raises pH to near-physiologic levels →
majority of anesthetic remains neutral/uncharged
→ more rapidly crosses nerve membranes
♦ Advantages: ↑ speed of onset and ↓ injection
pain (buffered anesthetic has physiologic pH,
vs. “injecting acid into skin”)
♦ Disadvantages: ↑ epinephrine degradation →
↓ shelf life (must use within 1 week)
♦ No need to buffer Plain lidocaine because it is
already pH 6
♦ Bupivicaine may precipitate if buffered with
bicarb; if used, it must be decreased to 0.1mL
bicarb per 10mL of Bupivicaine
Hyaluronidase
♦ Mechanism: digests hyaluronic acid
♦ Advantages: ↑ anesthetic diffusion, ↓ tissue distortion
♦ Disadvantages: ↓ duration, ↑ toxicity (due to
↑ absorption); contains contact allergen thimerosal
■
Lidocaine
Most commonly used local anesthetic
Anesthetic of choice for pregnant women
Most commonly used concentrations: 1% (10 mg/mL),
2% (20 mg/mL), and 0.1% tumescent (1 mg/mL)
Must know the maximum doses!
♦ Without epinephrine 5 4.5 to 5 mg/kg (31.5–
35 mL of 1% lidocaine in a 70-kg patient)
Pediatric 5 1.2 to 2 mg/kg (2.4–4 mL of 1%
lidocaine in a 20-kg patient)
♦ With epinephrine 5 7 mg/kg (49 mL of 1%
lidocaine in 70-kg patient)
Pediatric 5 3 to 4.5 mg/kg (6–9 mL of 1%
lidocaine in a 20-kg patient)
♦ Tumescent anesthesia 5 55 mg/kg
10-fold dilution of standard 1% lidocaine with
1:100,000 epinephrine (5 0.1% lidocaine with
1:1,000,000 epinephrine)
Advantages: ↓ bleeding, ↑ duration of
anesthesia, and avoids complications a/w
general surgery (↓ morbidity and mortality)
Caution w/ end-stage liver disease → ↑ risk of
lidocaine toxicity (metabolized by liver)
Pregnancy class B, lactation safe
• Adverse reactions to local anesthetics (Table 8.6)
■
Must know the presentations of the various adverse
reactions to local anesthetics!
■
Mnemonic: lidocaine overdose stages loosely resemble
alcohol overdose:
Mild (“Happily buzzed and tingly feeling”):
restlessness, euphoria, talkativeness, lightheadedness,
Table 8.6 Differential Diagnosis of Local Anesthetic Systemic Reactions
Diagnosis Pulse Rate Blood Pressure Signs and Symptoms Emergency Management
Vasovagal reaction Low Low Excess parasympathetic reaction; diaphoresis,
Epinephrine reaction High High
Anaphylactic reaction High Low Peripheral vasodilation w/ reactive tachycardia;
Lidocaine overdose
1–6 mcg/mL Normal Normal Circumoral and digital paresthesias, restlessness,
6–9 mcg/mL Normal Normal Nausea, vomiting, muscle twitching, tremors,
9–12 mcg/mL Low Low Seizures, cardiopulmonary depression Respiratory support
.12 mcg/mL
Modied from Meine JG. Local anesthetics. In: Vidimos AT, Ammirati CT, Poblete-Lopez C, eds. Requisites in Dermatology: Dermatologic Surgery . Philadelphia:
Elsevier; 2009, pp 49–57.
None None Coma; cardiopulmonary arrest Cardiopulmonary resuscitation and life
hyperventilation, and nausea
Excess a- and b-adrenergic receptor stimulation;
palpitations, muscle tremors, and nervousness
stridor, bronchospasm, urticaria, and angioedema
metallic taste, talkativeness, euphoria, and
lightheadedness
blurred vision, slurred speech, tinnitus, confusion,
excitement, and psychosis
Trendelenburg, cold compress, and
reassurance
Reassurance (typically short-lived),
phentolamine, and propranolol
SQ epinephrine 1:1000 (0.3 mL),
antihistamines, corticosteroids, fluids,
oxygen, and airway maintenance
Observation
Diazepam; airway maintenance
support
451

CHAPTER 8 • Dermatologic Surgery
“funny tingling” around mouth and hands, metallic
taste, and circumoral numbness
Moderate (“Hammered! Can’t hear or speak
well”): nausea, vomiting, psychosis, tinnitus,
muscle twitching/tremors, blurred vision, slurred
speech, and confusion
Severe (“Severe alcohol poisoning”): seizures
and cardiopulmonary depression
Life-threatening: coma and cardiopulmonary arrest
■
Easiest way to distinguish between vasovagal (most
common), epinephrine reaction, and anaphylaxis
(most severe) is to compare BP and HR
• Injection techniques to decrease pain (Boards fodder!):
■
Buffer w/ bicarbonate
■
Warm anesthetic to body temperature
■
Pretreat w/ topical anesthetics or ice packs
■
Use small diameter needle (30 gauge)
■
Mildly irritate (pinch, rub, Buzzy, ShotBlocker)
surrounding skin at the time of injection → decreases
transmission of pain signals to brain (“Gate theory”
of pain)
■
Inject slowly, starting deep in SQ → gradually move
supercial
■
Reintroduce needle at previously anesthetized areas
and fan out
■
Music and mental distraction also reduce the
perception of pain
• Regional blocks (see related discussion in Surgical
Anatomy section)
■
Facial: supraorbital, infraorbital, and mental nerves are
the most important (Figs. 8.6 and 8.7)
■
Feet: posterior tibial, saphenous, supercial peroneal,
and sural nerves (Figs. 8.3, 8.8, and 8.9)
■
Hand: median and ulnar nerves (Figs. 8.4 and 8.10)
SENSORY INNERVATION OF
THE CENTRAL FACE
SO
SO
ST
IT
AEIO IO
MM
AE External nasal branch of the
anterior ethmoidal nerve (V1)
IO Infraorbital nerve (V2)
IT Infratrochlear nerve (V1)
M Mental nerve (V3)
SO Supraorbital nerve (V1)
ST Supratrochlear nerve (V1)
Fig. 8.6 Sensory innervation of the central face. (From Hruza GJ. Anesthesia. In:
Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. Philadelphia:
Elsevier; 2018:2440–2449.)
Supratrochlear nerve
Supraorbital nerve
Infraorbital nerve
A
Fig. 8.7 Location and sensory distribution for nerve blocks. (A) Supraorbital and supratrochlear nerve block. (B) Infraorbital nerve block. (C) Mental nerve block. (From
Soriano TT, Breithaupt A, Chesnut C. Anesthesia and analgesia. In: Robinson JK, Hanke CW, Siegel DM, Fratila A, eds. Surgery of the Skin. 3rd ed. Philadelphia,
Elsevier, 2015:43–63.)
B C
Mental nerve
452

8.2 Local Anesthetics and Perioperative Pain Control
Extensor hallucis
longus tendon
Superficial
peroneal
nerve
Fibula
Sural nerve
Achilles tendon
Fig. 8.8 Nerve blocks of the ankle. Transverse section of the right leg above the
malleoli. (From Soriano TT, Breithaupt A, Chesnut C. Anesthesia and analgesia.
In: Robinson JK, Hanke CW, Siegel DM, Fratila A, eds. Surgery of the Skin. 3rd
ed. Philadelphia, Elsevier, 2015:43–63.)
SUPERFICIAL PERONEAL, SAPHENOUS
AND DEEP PERONEAL NERVE BLOCKS
Superficial peroneal nerve
Deep peroneal nerve
Lateral malleolus
Fig. 8.9 Supercial peroneal, saphenous, and deep peroneal nerve blocks.
Great toe dorsiexion aids in visualizing the extensor hallucis longus tendon.
(From Hruza GJ. Anesthesia. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Der-
matology. 4th ed. Philadelphia: Elsevier; 2018:2440–2449.)
■
Fingers (digital block): two dorsal and two volar nerves
Anterior tibial artery
Deep peroneal nerve
Tibia
Great
saphenous vein
Posterior
tibial artery
Posterior tibial nerve
Saphenous nerve
Subcutaneous injection
malleolus-to-malleolus
Medial malleolus
Deep peroneal
nerve block
Extensor hallucis longus
MedialLateral
Saphenous
nerve
run along sides of nger
Lidocaine w/ epinephrine safe if no history of
vascular disease
Proximal block: needle inserted at base of digit, do
not exceed 4 mL total (risk of tourniquet effect,
esp. if >8 mL)
Wing block: achieves more rapid anesthesia, but
more painful during injection; needle inserted 3 mm
Median nerve
block
Flexor carpi
radialis tendon
Palmaris longus
tendon
Flexor carpi
ulnaris tendon
Ulnar nerve
block
Fig. 8.10 Landmarks for median and ulnar nerve blocks . Nerve blocks are
delivered by insertion of needles at the proximal crease of the wrist. (Modied
from Soriano TT, Breithaupt A, Chesnut C. Anesthesia and analgesia. In: Robinson JK, Hanke CW, Siegel DM, Fratila A, eds. Surgery of the Skin. 3rd ed. Philadelphia: Elsevier; 2015:43–63.)
proximal to junction of proximal nail fold (PNF)
and lateral nail fold (LNF) → intradermal injection
along the PNF → withdraw and redirect along LNF
■
Risks of nerve blocks: nerve injury, vessel trauma, and
intravascular inltration
• Topical anesthetics
■
Stratum corneum limits penetration → mucosal sites
benet more
■
Boards fodder:
Eutectic mixture of local anesthesia (EMLA): mixture
of 2.5% lidocaine 1 2.5% prilocaine; requires
occlusion; risk of methemoglobinemia
in infants from prilocaine; cannot use near eye
(→ corneal injury); on histology, causes artifactual
swelling and vacuolization of upper epidermis 1
basal layer split
LMX4 (lidocaine 4%): unlike EMLA, does not
require occlusion
Cocaine: only ester anesthetic to cause
vasoconstriction (all others → vasodilation); used
on nasal mucosa
Benzocaine (Anbesol™) and lidocaine jelly: used on
mucous membranes
Proparacaine and tetracaine: used for ocular/
conjunctival anesthesia
• True allergies to local anesthetic are rare!
■
More common: vasovagal reaction (#1) or epinephrine
sensitivity
■
Allergic reactions usually due to preservatives
(methylparaben or metabisulte preservatives in
amides; or PABA in esters)
■
Amides do not cross-react w/ esters
• Adjunctive pain/anxiety-control measures:
■
Preoperative anxiolytic
Benzodiazepines (diazepam and midazolam):
generally safe; can reverse overdose w/flumazenil
■
Conscious sedation (aka “procedural sedation and
analgesia”)
Short-acting analgesic 1 sedative → decreased
consciousness without need for airway management;
requires cardiopulmonary monitoring
453

CHAPTER 8 • Dermatologic Surgery
■
Postoperative pain management
Pain is maximal on night of surgery → drops
dramatically each additional day after surgery
♦ Severe pain should not be experienced for .4 to
5 days → if so, consider drug-seeking behavior,
infection, or hematoma
Rest, Ice, Compression, Elevation (RICE)
Acetaminophen
♦ Acetaminophen maximum dose/24 hours 5 4 g
(,60 yo) or 3 g (.60 yo)
♦ In setting of liver failure, 2 g/24 hours of
acetaminophen alone is safer than either NSAIDs
or narcotic
♦ Combining w/ NSAID superior to either agent
alone, but slight ↑ bleeding risk
Opioids
♦ Occasionally necessary (taut scalp/forehead/large
trunk closures)
8.3 SURGICAL INSTRUMENTS AND NEEDLES
• Gold-colored instrument handles: indicates presence of
tungsten carbide
■
Used in many surgical instruments: needle drivers,
forceps, scissors, etc.
■
Tungsten carbide is harder and more durable than
stainless steel
• Scalpel handles
■
Bard-Parker: standard at handle (#3, most common)
holds common blades (#15, #15C, #10, #11)
■
Beaver: round or hexagonal; holds smaller, sharper
blades; useful for conned spaces or delicate tissue;
specic blades (#64, #67)
• Scissors
■
General principles
Short-handled scissors useful for delicate work
Long-handled scissors extend the surgeons reach
and are useful for undermining
Curved blades useful for undermining cysts
Straight blades useful for trimming tissue and
cutting sutures
Serrated blades grab tissue better
Sharp-tipped scissors puncture tissue easily and are
best for dissection
Blunt-tipped scissors are best for delicate undermining
■
Scissor types
Iris scissors: sharp-tipped and short-handled; blades
may be straight or curved; best for sharp dissection
Gradle scissors: similar to iris but blades curved
and tapered to a ne point at tip; best for delicate
tissue (e.g., periorbital)
Westcott and Castroviejo scissors: sharp, netipped, spring-loaded; good for eyelid
Mayo scissors: characterized by 1:1 handle-toblade ratio; primary purpose is coarse dissection
Metzenbaum scissors: long handles with blunt tips
→ useful for blunt dissection in areas that require
long reach
O’Brien scissors: angled blade for delicate suture cutting
Supercut scissors: one blade has a razor edge;
“supercut” blades are available on most scissor types
listed above and often are denoted with black handles
• Needle drivers
■
Wide variety; Webster and Halsey are popular
■
General principles
Smaller needle drivers with smooth jaws
♦ Ideal for small, delicate needles and work on face
♦ Advantages: smooth jaws have ↓ risk of tearing
small sutures (6-0 and smaller) and are less
damaging to ne needles (P-3 and smaller)
♦ Disadvantages: needles not grasped as tightly as
with serrated needle drivers → ↑ needle twisting
♦ Caution: larger needles will ruin small needle drivers
Larger, serrated jaws
♦ Ideal for larger needles and work on trunk and
extremities
♦ Advantages: serrated jaws hold needles more
securely (prevents twisting)
♦ Disadvantage: damages delicate needles, shreds
small sutures
• Forceps
■
General principles
Serrated forceps: easier to grasp needle, but results
in ↑ tissue crush injury
Toothed forceps: harder to grasp needle, but handles
tissue gently (↓ crush injury)
Combination forceps: distal teeth for tissue
handling w/ proximal platform for suture grasping
→ allows for gentle tissue handling and easier
grasping of needle
■
Forceps types
Adson forceps: most commonly used and most
versatile
Bishop-Harmon and Pauque forceps: small, ne-
tipped instruments; most useful for delicate tissues
(e.g., eyelid)
♦ Bishop-Harmon has three holes in handles to
make them lighter in weight and easier to grip
Jeweler’s forceps: extremely ne tip; suture removal
on ne skin (eyelids) and spitting suture removal
• Other instruments
■
Hemostats: used to grasp bleeding vessels before
ligation
■
Skin hooks: available in many forms;
“Skin rake”: a skin hook with multiple hooks
Hooks are the least traumatic way to handle tissue
(during electrosurgery and suturing), but are a
sharps hazard
■
Periosteal elevator: used to remove periosteum or
separate nail plate from nail bed
■
Chalazion clamp: useful for eyelid surgery or on the lip
to stop bleeding
• Surgical needles
■
Needle is composed of three parts:
Shank (swage): swaged portion that attaches to
suture; weakest part of needle → do NOT grasp
here, it will bend or break the needle
♦ Size of suture track is determined by shank size,
not suture size
454
Соседние файлы в папке Библиотека им академика М.И. Перельмана
